Trial intelligence / Profile preview

Bosentan for high-risk outpatients with COVID-19

IRCT20211203053263N1Phase 3Completed

Sponsor
Ilam University of Medical Sciences
Start
Dec 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Bosentan with Placebo (2 arms). Primary endpoint: Disease progression. Started Dec 2021; status: completed.

02

Drugs

bosentan
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on IRCT20211203053263N1.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20211203053263N1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call